AVENTACELL BIOMEDICAL CORP

Overview

AVENTACELL BIOMEDICAL CORP is an active pharmaceutical ingredient (API) supplier with 4 active FDA Type II Drug Master Files, covering EXOSOME-DEPLETED ULTRAGROTM- PURE GI; HUMAN FIBRINOGEN DEPLETED PLATELET LYSATE; HUMAN FIBRINOGEN DEPLETED PLATELET LYSATE XENO FREE; ULTRAGRO - PURE GI.

API / Drug Master Files

AVENTACELL BIOMEDICAL CORP holds 4 active (4 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• EXOSOME-DEPLETED ULTRAGROTM- PURE GIActive2025-02-21
• ULTRAGRO - PURE GIActive2019-12-13
• HUMAN FIBRINOGEN DEPLETED PLATELET LYSATE XENO FREEActive2019-07-22
• HUMAN FIBRINOGEN DEPLETED PLATELET LYSATEActive2019-05-27

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to AVENTACELL BIOMEDICAL CORP in our records. PharmaTek screens the full directory against live FDA enforcement data.